Literature DB >> 17071498

CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells.

Kyoko Haraguchi1, Tsuyoshi Takahashi, Fumio Nakahara, Akihiko Matsumoto, Mineo Kurokawa, Seishi Ogawa, Hideaki Oda, Hisamaru Hirai, Shigeru Chiba.   

Abstract

Invariant natural killer T (iNKT) cells are thought to regulate anti-tumor immunity. Human iNKT (i.e. Valpha24+ NKT) cells have been reported to recognize CD1d on target cells and show cytotoxicity directly on the target cells in vitro. However, the anti-tumor effect of mouse iNKT (i.e. Valpha14+ NKT) cells has been repeatedly reported to be dependent on the activity of natural killer (NK) cells via interferon-gamma, with no evidence of direct cytotoxicity. In the present study, we report that in vitro cytolysis of EL-4 mouse lymphoblastic lymphoma cells by Valpha24+ NKT cells and in vivo eradication of these cells are both dependent on the level of CD1d expression on the tumor cell surface. These observations possibly suggest that direct cytotoxicity of tumor cells by iNKT cells is common to both humans and mice, and that the high expression level of CD1d may be a predictor whether the tumor is a good target of iNKT cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17071498     DOI: 10.1080/10428190600682688

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  25 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

Review 2.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

3.  The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma.

Authors:  Laura Escribà-Garcia; Carmen Alvarez-Fernández; Ana Carolina Caballero; Robert Schaub; Jorge Sierra; Javier Briones
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

4.  Tumor immunology viewed from alternative animal models-the Xenopus story.

Authors:  Maureen Banach; Jacques Robert
Journal:  Curr Pathobiol Rep       Date:  2017-01-26

5.  Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.

Authors:  Rupali Das; Peng Guan; Susan J Wiener; Nishant P Patel; Trevor G Gohl; Elizabeth Evans; Maurice Zauderer; Kim E Nichols
Journal:  Blood Adv       Date:  2019-03-12

6.  CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.

Authors:  Pei-Ming Yang; Pei-Jie Lin; Ching-Chow Chen
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

7.  Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.

Authors:  Gerhard Wingender; Philippe Krebs; Bruce Beutler; Mitchell Kronenberg
Journal:  J Immunol       Date:  2010-07-26       Impact factor: 5.422

8.  Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.

Authors:  Gourapura J Renukaradhya; Masood A Khan; Marcus Vieira; Wenjun Du; Jacquelyn Gervay-Hague; Randy R Brutkiewicz
Journal:  Blood       Date:  2008-04-16       Impact factor: 22.113

Review 9.  The role of natural killer T cells in B cell malignancies.

Authors:  Ghasem Ghalamfarsa; Abolghasem Hadinia; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2013-03-19

10.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.

Authors:  Liping Song; Shahab Asgharzadeh; Jill Salo; Kelly Engell; Hong-wei Wu; Richard Sposto; Tasnim Ara; Ayaka M Silverman; Yves A DeClerck; Robert C Seeger; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.